Literature DB >> 8435326

Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride.

L Condamine1, O Hermine, P Alvin, M Levine, C Rey, V Courtecuisse.   

Abstract

We report one case of acquired sideroblastic anaemia in a patient treated for Wilson's disease with triethylene tetramine dihydrochloride (TTH). No other cause of acquired sideroblastic anaemia was found, and neither iron nor pyridoxine therapy could correct this anaemia. In contrast, decreasing the dose of TTH led to disappearance of ringed sideroblasts. Thus TTH should be added as a further cause of secondary acquired sideroblastic anaemia. The pathophysiology of this finding, probably linked to an abnormality of mitochondrial iron metabolism, is briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435326     DOI: 10.1111/j.1365-2141.1993.tb04648.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Cytopenia and Bone Marrow Dysplasia in a Case of Wilson's Disease.

Authors:  Aarathi R Rau; M Usha; Pooja Mallya; A T K Rau
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-07       Impact factor: 0.900

Review 2.  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.

Authors:  Garth J S Cooper
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

3.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

4.  A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.

Authors:  Yu-Fang Huang; Macus Tien Kuo; Yi-Sheng Liu; Ya-Min Cheng; Pei-Ying Wu; Cheng-Yang Chou
Journal:  Front Oncol       Date:  2019-05-24       Impact factor: 6.244

5.  Drug-induced hematologic syndromes.

Authors:  David M Mintzer; Shira N Billet; Lauren Chmielewski
Journal:  Adv Hematol       Date:  2009-07-07

6.  Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.

Authors:  Jun Lu; Beau Pontré; Stephen Pickup; Soon Y Choong; Mingming Li; Hong Xu; Gregory D Gamble; Anthony R J Phillips; Brett R Cowan; Alistair A Young; Garth J S Cooper
Journal:  Cardiovasc Diabetol       Date:  2013-01-31       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.